An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies is a phase 2 interventional study registered as NCT07668453 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 30 participants, started 2025-10-20 and due to reach its primary completion in 2027-06-30. Interventions recorded: Adebrelimab, gemcitabine, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Biliary Tract Neoplasms. Sites: China. No results are recorded here; the registry entry is the source.